Navigation Links
Ongoing Progress of MitraClip(R) Therapy Highlighted at TCT 2009
Date:9/15/2009

MENLO PARK, Calif., Sept. 15 /PRNewswire/ -- The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to take place in San Francisco from September 21-25, will serve as a backdrop for the presentation of EVEREST registry clinical results of the MitraClip(R) therapy for patients with mitral regurgitation (MR). MR is the most common type of heart valve insufficiency in the United States and Europe, and affects millions of people worldwide. The MitraClip(R) therapy provides a non-surgical treatment option for patients suffering from the effects of functional or degenerative MR.

Among oral presentations at TCT 2009, EVEREST investigators as well as independent physicians will report data related to the clinical impact of reduction of MR and the histopathology of the MitraClip(R) device collected as part of the EVEREST registry studies. The data are from the preliminary cohort of the first 107 patients as well as from patients enrolled in the high risk registry. Other presentations at TCT 2009 will discuss the EVEREST study design, procedure simulation and clinical outcomes of patients treated in Europe following CE Mark.

Highlights of the data to be presented at TCT 2009 include:

Tuesday, September 22

  • "Successful MitraClip(R) Therapy Results in Favorable Sept-Lateral Mitral Annular Diameter and Left Ventricular Remodeling"; Saibal Kar, M.D. will present 12-month results of functional MR patients from the EVEREST II High Risk Registry arm on Tuesday at 10:15 a.m. in room 113.
  • "Long-Term Histologic Response Following MitraClip(R) Implantation"; Renu Virmani, M.D. will present data on the healing response in patients from the EVEREST I and EVEREST II trials from 301 to 1878 days after treatment on Tuesday at 11:15 a.m. in room 113.
  • "Significant Reverse
    '/>"/>

SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer
2. A Heart Healthy Diet and Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline as We Age
3. iJET Provides Additional Services in Response to Ongoing H1N1 Influenza A (Swine Flu) Developments
4. UPMC Health Plan Provides Ongoing Support of HEALTHY Armstrong Initiative
5. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
6. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
7. Ongoing worldwide shortage of medical isotopes could threaten patient care, says expert
8. Food Safety Expert: Americans Not Aware of Ongoing Risk & Complications of Salmonella Poisoning
9. Stimulus Bill Requires Modification in U.S. Senate to Better Protect Seniors Ongoing Access to Quality Nursing Home Care
10. Window World Cares Raises $160,000 for St. Jude Childrens Hospital, Commits to Ongoing Support
11. New Study Disputes Ongoing Controversy Over Memory Screenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... By Amanda Gardner HealthDay Reporter , MONDAY, July ... evidence proving that staying in shape and eating right are ... that over 8 million Americans have histories of heart attack, ... the message seriously. That,s the theme of a new ...
... about clinical trials for drugs that have been approved ... health risks, an independent committee at the Institute of ... has developed a conceptual framework to guide the agency ... drug-safety trials. The recommendations of the committee, requested ...
... Parkinson disease patients aren,t walking talls ... alleviated with drugs that target dompamine, a chemical in ... and therefore known as a neurotransmitter. However, such drugs ... commonly affect individuals with severe and advanced forms of ...
... Calif., July 12, 2010 UC Irvine public health ... in impoverished reaches of China, Myanmar and Thailand, thanks ... of a seven-year, $14.5 million award to Pennsylvania State ... Diseases. Yan will collaborate with Penn State principal investigator ...
... Drinking tart cherry juice daily could help reduce the severity ... according to a new study published in the Journal ... University of Pennsylvania, University of Rochester and VA Center of ... of 15 older adults. The adults drank 8 ounces of ...
... that roams with only limited control among the rural poor ... cruzi is the triatomine insect, or "kissing bug," which thrives ... sucks the blood of mammals, helping T. cruzi ... to lie on porches or other areas easily accessible to ...
Cached Medicine News:Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 2Health News:Lifestyle Interventions Needed to Stay Heart-Healthy 3Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 2Health News:Hopkins faculty lead development of report to FDA on ethical, scientific issues related to 'post-market' clinical trials 3Health News:JCI online early table of contents: July 12, 2010 2Health News:JCI online early table of contents: July 12, 2010 3Health News:JCI online early table of contents: July 12, 2010 4Health News:JCI online early table of contents: July 12, 2010 5Health News:JCI online early table of contents: July 12, 2010 6Health News:JCI online early table of contents: July 12, 2010 7Health News:JCI online early table of contents: July 12, 2010 8Health News:New study suggests tart cherry juice can be a natural solution for insomnia 2Health News:Dogs may help collar Chagas disease 2
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) announced ... second quarter dividend of $0.1025 per share. This dividend is payable ... 17, 2011.   ABOUT HILL-ROM HOLDINGS, ... and provider of medical technologies and related services for the health ...
... and SYDNEY, March 7, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Healthcare Conference at 8:00 a.m. Eastern Time on Tuesday, ...
Cached Medicine Technology:HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
Inquire...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
Medicine Products: